<DOC>
	<DOCNO>NCT01717638</DOCNO>
	<brief_summary>It Phase 3 extension study V72P12E1 ( NCT00944034 ) . The main aim second extension study explore bactericidal antibody persistence 4-year-old child fourth dose boost rMenB+OMV NZ two-dose catch-up schedule rMenB+OMV NZ administer toddler part respective vaccination course study V72P12E1 . In addition , study characterize antibody response fifth dose boost child receive three-dose primary series rMenB+OMV NZ 2 , 3 , 4 month age ( parent study V72P12 , NCT00721396 ) , subset child receive three-dose primary series rMenB+OMV NZ 2 , 4 , 6 month age ( parent study V72P12 ) . Antibody response also characterize third dose boost rMenB+OMV NZ administer approximately 4 year age child receive two catch-up dos rMenB+OMV NZ toddler study V72P12E1 . Finally , safety immunogenicity two catch-up dos rMenB+OMV NZ administer 2 month apart healthy naïve child 4 year age assess .</brief_summary>
	<brief_title>Persistence Antibody Levels Response Fifth Third Meningococcal B Recombinant Vaccine 4-year Old Healthy Children Who Previously Participated Study V72P12E1</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>A . Inclusion Criteria naïve subject , newly enrol ( B48_50 ) : 1 . 4 year old ( 48 60 month ) healthy male female subject recruit site study V72P12E1 . The age window define first day subject turn 4 year old day subject turn 5 year old . 2 . For parent/legal guardian ( ) give write informed consent nature study explain . 3 . For parent/legal guardian ( ) confirm availability visit ( ) schedule study . 4 . In good health determine medical history , physical examination , clinical judgment investigator . B . Inclusion Criteria followon participant ( Groups B+R246 12_48 , B+R246 18_48 , B+R246 24_48 , B246 12_48 , B246 18_48 , B246 24_48 , B+R234 12_48 , B+R234 18_48 , B+R234 24_48 , B12 14_48 , B18 20_48 , B24 26_48 ) : Inclusion criterion Group B48_50 , addition subject complete vaccination course V72P12E1 study . A. Exclusion Criteria naïve subject , newly enrol ( Group 7 ) : 1 . Subjects whose parents/legal guardian unwilling unable give write informed consent participate study . 2 . History meningococcal B vaccine administration . 3 . Previous ascertain suspected disease cause N. meningitidis . 4 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis . 5 . History allergic reaction vaccine component . 6 . Significant chronic infection . 7 . Any serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , diabetes mellitus Type I , cardiac disease , hepatic disease , progressive neurological disease seizure , either associate fever part underlie neurological disorder syndrome , autoimmune disease , HIV infection AIDS , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) . 8 . Known suspected impairment/alteration immune system result ( example ) receipt chronic immunosuppressive therapy immunostimulants . 9 . Participation another clinical trial within 90 day prior enrolment plan study . 10 . Family member household member research staff . 11 . Any condition , opinion investigator , might interfere evaluation study objective . B. Exclusion Criteria followon participant ( ( Groups B+R246 12_48 , B+R246 18_48 , B+R246 24_48 , B246 12_48 , B246 18_48 , B246 24_48 , B+R234 12_48 , B+R234 18_48 , B+R234 24_48 , B12 14_48 , B18 20_48 , B24 26_48 ) : Exclusion criterion Group B48_50 , exception criterion 2 exclude participation V72P12E1 criterion 9 .</criteria>
	<gender>All</gender>
	<minimum_age>48 Months</minimum_age>
	<maximum_age>60 Months</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Meningococcal disease , vaccine , child , persistence</keyword>
</DOC>